Ethylene oxide (EO) residue testing for in vitro diagnostic (IVD) reagents is a critical quality control and biocompatibility requirement for EO-sterilized kit components such as test cassettes, cartridges, swabs, and collection devices. This article explains the applicable standards, permissible residue limits, sample types, headspace gas chromatography methods, and common regulatory questions to help IVD manufacturers achieve compliant batch release and product registration.
Technical Overview
Ethylene oxide (EO, CAS 75-21-8) sterilization is one of the most widely used low-temperature sterilization processes for heat- and moisture-sensitive components of in vitro diagnostic (IVD) reagent kits, including lateral-flow test cassettes, microfluidic cartridges, sample collection swabs, and transfer devices. Because EO is a potent alkylating agent classified as a Group 1 human carcinogen by IARC, and because it reacts with chloride ions to form the toxic degradation product ethylene chlorohydrin (ECH, 2-chloroethanol), residual EO in sterilized IVD products must be strictly controlled and verified through validated analytical testing.
Residual EO can migrate from sterilized plastic components into liquid reagents, calibrators, controls, and patient samples, where it may alkylate functional groups on enzymes, antibodies, and chromogenic substrates, distort analytical signals, and expose laboratory personnel and patients to unnecessary toxicological risk. For this reason, both the sterilization process and the resulting residue levels are governed by a well-established framework of international and national standards:
- ISO 11135 and GB 18279.1 — validation and routine control of ethylene oxide sterilization processes
- ISO 10993-7 and GB/T 16886.7 — biological evaluation of medical devices, EO sterilization residuals, and permissible limits
- GB/T 14233.1 — chemical analysis methods for medical device products, including headspace gas chromatographic determination of EO and ECH residues
- ISO 10993-12 — sample preparation and reference materials for biological and chemical evaluation
Under ISO 10993-7 and its Chinese adoption GB/T 16886.7, the deliverable EO dose shall not exceed 4 mg per device for limited patient exposure (less than 24 hours), 2 mg for prolonged exposure (24 hours to 30 days), and 0.1 mg for permanent-contact devices, with separate and generally higher limits defined for ECH. In China, many IVD product standards and registration technical documents additionally apply an acceptance criterion of no more than 10 μg of EO per gram of product, determined in accordance with GB/T 14233.1.
Testing Samples
EO residue testing applies to every component of an IVD kit that is directly exposed to EO sterilization or that contacts EO-sterilized parts during storage. Samples should be retained in their original sterile packaging, transported and stored at low temperature in sealed containers, and analyzed promptly, because EO is volatile and residues decline over time. Typical sample categories include:
Rapid Test Cassettes and Immunochromatographic Strips
Cassette housings, shells, absorbent pads, and desiccant-containing packaging for lateral-flow immunoassays are frequently EO-sterilized and constitute the highest-volume category of EO residue testing in the IVD sector.
Microfluidic Cartridges and Analyzer-Specific Consumables
Cassettes, cuvettes, sample cups, and lab-on-chip cartridges used in chemistry, immunoassay, coagulation, and blood gas analyzers may be sterilized with EO due to their complex, heat-sensitive assemblies, and are tested for both EO and ECH residues.
Sample Collection and Transport Devices
Nasopharyngeal and oropharyngeal swabs, specimen collection tubes, transport medium containers, droppers, and closure caps are commonly EO-sterilized and require residue verification as patient-contacting components.
Reagent Containers, Closures, and Packaging Materials
Bottles, stoppers, blister trays, and breathable sterile barrier packaging that contact sterile reagents or components are tested to evaluate residual migration into reagent formulations over the shelf life of the kit.
Testing Items
The core scope of an EO residue study for IVD reagents typically includes the following items, each reported as a quantitative result with a clear pass or fail conclusion against the applicable acceptance criteria:
- Ethylene oxide (EO) residue content, expressed in μg/g of sample and in mg per device
- Ethylene chlorohydrin (ECH, 2-chloroethanol) residue content, expressed in μg/g and mg per device
- Total residual load per device and calculation of the deliverable dose according to ISO 10993-7
- Comparison of results with limits specified in product standards, registration dossiers, or ISO 10993-7 exposure-duration categories
- Optional migration studies assessing residue transfer from plastic components into liquid reagents under accelerated and real-time storage conditions
Testing Methods
Sample Preparation and Extraction
Sample preparation follows ISO 10993-12 and GB/T 14233.1. Components are cut into pieces of defined dimensions, accurately weighed, and extracted either by simulated-use extraction in water at physiological temperature or by exhaustive extraction to determine the total residual burden. For solid plastic components, weighed portions may be introduced directly into headspace vials with a defined volume of water to allow in-vial partitioning of EO into the gas phase during heating.
Headspace Gas Chromatography with Flame Ionization Detection (HS-GC-FID)
Static headspace gas chromatography is the reference technique for EO quantification. Sealed vials are equilibrated in a heated headspace oven, typically at 60 to 80 degrees Celsius for 20 to 40 minutes, after which the equilibrated gas phase is automatically injected into a gas chromatograph equipped with a capillary column of suitable polarity and a flame ionization detector. Quantification is performed by external calibration using certified EO standard solutions, with matrix-matched calibration or standard addition employed where matrix effects are significant. Detection limits at or below 0.5 μg/g, and typically near 0.1 μg/g, are routinely achievable, which comfortably supports compliance decisions against the 10 μg/g criterion.
Determination of Ethylene Chlorohydrin
Because ECH is more polar and less volatile than EO, it is commonly determined by gas chromatography with flame ionization detection using direct injection of the aqueous extract, or by optimized headspace procedures with a polar capillary column. ECH results are evaluated against the corresponding limits in ISO 10993-7 or the applicable product standard.
Method Validation and Quality Control
Methods are validated in accordance with ISO/IEC 17025 quality principles and cover linearity across the working range (typically correlation coefficients of at least 0.995), accuracy by spike recovery (commonly 80 to 120 percent), precision with relative standard deviations below 10 percent, limits of detection and quantification, and measurement uncertainty. Each analytical sequence includes calibration verification standards, blank controls, duplicate preparations, and spiked recovery samples. Manufacturers are advised to engage accredited third-party laboratories with validated methods and demonstrated experience in medical device residue analysis.
Applications
EO residue data for IVD reagents serve multiple purposes across the product lifecycle:
- Sterilization process validation under ISO 11135 and GB 18279.1, including residue accumulation studies across sterilization and aeration cycles
- Routine batch release testing as part of finished product quality control
- Regulatory submissions, including NMPA registration type testing, EU technical documentation for CE marking, and FDA premarket submissions
- Shelf-life and stability studies evaluating residue decay and migration into reagents over time
- Research and development support for material selection, packaging design, and aeration cycle optimization
- Investigation of out-of-specification results, customer complaints, and process deviations
FAQ
Why do IVD reagents require EO residue testing if the liquid reagents themselves are not EO-sterilized?
Although liquid reagent formulations are typically sterilized by filtration or supplied preservative-sterile, the kit components that contact them, such as cassettes, swabs, cartridges, and closures, are frequently EO-sterilized. Residual EO and ECH in these components can migrate into reagents and patient samples, degrade biological components such as enzymes and antibodies, and present a toxicological and biocompatibility risk, which is why residue verification is required.
What are the applicable limits for EO residues?
ISO 10993-7 and GB/T 16886.7 specify maximum deliverable EO doses of 4 mg per device for limited exposure (less than 24 hours), 2 mg for prolonged exposure (24 hours to 30 days), and 0.1 mg for permanent contact, together with separate limits for ECH. In addition, Chinese IVD product standards and registration requirements commonly specify EO residues not exceeding 10 μg/g of product tested according to GB/T 14233.1.
Which analytical method is preferred, and why?
Headspace gas chromatography with flame ionization detection is the preferred method because it combines high sensitivity and selectivity with minimal sample matrix interference, automatic sample preparation, and direct comparability with the procedures described in GB/T 14233.1 and ISO 10993-7.
When should samples be collected after sterilization?
Samples should be collected after the validated aeration and degassing period defined in the sterilization specification, and should represent worst-case load positions in the sterilization chamber. Because EO continues to dissipate over time, sampling timing must be fixed in the sampling plan so that results remain conservative and comparable between batches.
Can EO residues actually affect analytical performance of an assay?
Yes. EO is a strong alkylating agent that can react with amino, sulfhydryl, and hydroxyl groups on proteins, enzymes, antibodies, and dyes. Even at low levels, migrated residues may reduce signal intensity, increase background, shorten reagent shelf life, and contribute to lot-to-lot variability, which is an additional practical motivation for residue control beyond toxicological compliance.
How can manufacturers reduce EO residues in IVD products?
Effective measures include optimizing aeration temperature, duration, and airflow; maximizing breathable packaging area; improving load configuration and density; selecting lower-absorbing polymer materials; and considering alternative sterilization methods, such as electron beam or gamma irradiation, where the product design and reagent chemistry permit.